<?xml version="1.0" encoding="UTF-8"?>
<p>It is important to provide general considerations that are scientifically valid as the Japanese regulatory authority because the underutilization of M&amp;S by domestic companies in Japan was pointed out by the industry speaker in session 1 of the workshop. Comments to these two draft guidelines (i.e., guidelines or ER analysis and guidelines for PBPK model analysis), were solicited from experts in overseas regulatory authorities, including the US Food and Drug Administration in the United States and the European Medicines Agency that have provided guidances for M&amp;S.
 <xref rid="psp412554-bib-0005" ref-type="ref">
  <sup>5</sup>
 </xref>, 
 <xref rid="psp412554-bib-0006" ref-type="ref">
  <sup>6</sup>
 </xref>, 
 <xref rid="psp412554-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="psp412554-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref>, 
 <xref rid="psp412554-bib-0009" ref-type="ref">
  <sup>9</sup>
 </xref> The new guidelines that have been developed by the AMED research group are expected not only to promote appropriate utilization of M&amp;S for regulatory purpose in Japan but also to serve as an agenda for future harmonizing activities.
</p>
